✦ LIBER ✦

Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa

✍ Scribed by Kristin E. Anderson; Thomas A. Sellers; Ping-Ling Chen; Stephen S. Rich; Ching-Ping Hong; Aaron R. Folsom

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 79 KB
Volume: 79
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970201)79:3<494::aid-cncr10>3.0.co;2-z

No coin nor oath required. For personal study only.

✦ Synopsis

acterized by infertility

📜 SIMILAR VOLUMES

Association of Stein-Leventhal Syndrome

Association of Stein-Leventhal Syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa

✍ Fabio Parazzini; Carlo La Vecchia; Silvia Franceschi; Renato Talamini; Eva Negri 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 2 views

Effect of the potent aromatase inhibitor

Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma

✍ Luis A. M. Costa; Michael S. Kopreski; Laurence M. Demers; Vernon M. Chinchilli; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 1 views

## Background: Fadrozole hydrochloride (cgs 16949a) is a highly potent, nonsteroidal aromatase inhibitor that significantly lowers estrogen levels in postmenopausal women and can be effective therapy for patients with advanced hormone-dependent breast carcinoma. circulating estradiol, estrone, and

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace